BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35044553)

  • 21. High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection.
    Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Cerruto MA; Brunelli M; Siracusano S; Artibani W
    Asian J Androl; 2020; 22(3):323-329. PubMed ID: 31347517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body Mass Index and prostatic-specific antigen are predictors of prostate cancer metastases in patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection.
    Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Cacciamani GE; Brunelli M; Siracusano S; Cerruto MA; Artibani W
    Minerva Urol Nefrol; 2019 Oct; 71(5):516-523. PubMed ID: 31241272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standardized and Simplified Robot-assisted Superextended Pelvic Lymph Node Dissection for Prostate Cancer: The Monoblock Technique.
    Mattei A; Würnschimmel C; Baumeister P; Hyseni A; Afferi L; Moschini M; Mordasini L; Grande P
    Eur Urol; 2020 Sep; 78(3):424-431. PubMed ID: 32327264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer.
    Porcaro AB; De Luyk N; Corsi P; Sebben M; Tafuri A; Processali T; Mattevi D; Pirozzi M; Cerruto MA; Amigoni N; Rizzetto R; Brunelli MA; Migliorini F; Siracusano S; Artibani W
    Urol Int; 2017; 99(4):392-399. PubMed ID: 28486228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Undetectable PSA after radical prostatectomy is more likely in low burden N+ prostate cancer patients when an extended lymph node dissection is performed.
    Ramírez-Backhaus M; Mir Maresma MC; Mascarós JM; Bertolo R; Hernández J; Gómez Ferrer A; Casanova-Ramón Borja J; Domínguez Escrig JL; Collado-Serra A; Calatrava Fons A; Rubio-Briones J
    Actas Urol Esp (Engl Ed); 2019 Nov; 43(9):480-487. PubMed ID: 31174878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The factors that affect the prediction of lymph node metastasis in prostate cancer.
    Turk H; Ün S; Koca O; Cinkaya A; Kodaz H; Zorlu F
    J Cancer Res Ther; 2018; 14(5):1094-1098. PubMed ID: 30197355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical implications of endogenous testosterone density on prostate cancer progression in patients with very favorable low and intermediate risk treated with radical prostatectomy.
    Porcaro AB; Tafuri A; Panunzio A; Cerrato C; Bianchi A; Gallina S; Vidiri S; D'Aietti D; Serafin E; Mazzucato G; Princiotta A; Brusa D; Brunelli M; Pagliarulo V; Cerruto MA; Antonelli A
    Asian J Androl; 2023 Jan; 25(5):556-63. PubMed ID: 36629157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection.
    Draulans C; Everaerts W; Isebaert S; Van Bruwaene S; Gevaert T; Oyen R; Joniau S; Lerut E; De Wever L; Laenen A; Weynand B; Defraene G; Vanhoutte E; De Meerleer G; Haustermans K
    J Urol; 2020 Apr; 203(4):713-718. PubMed ID: 31718396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative endogenous testosterone density predicts disease progression from localized impalpable prostate cancer presenting with PSA levels elevated up to 10 ng/mL.
    Porcaro AB; Bianchi A; Mazzucato G; Gallina S; Serafin E; Tafuri A; Cerrato C; Panunzio A; Vidiri S; D'Aietti D; Orlando R; Brusa D; Brunelli M; Siracusano S; Cerruto MA; Antonelli A
    Int Urol Nephrol; 2023 Jan; 55(1):85-92. PubMed ID: 36197572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence of the indication to European Association of Urology guideline recommended pelvic lymph node dissection at a high-volume center: Differences between open and robot-assisted radical prostatectomy.
    Schiffmann J; Haese A; Leyh-Bannurah SR; Salomon G; Steuber T; Schlomm T; Boehm K; Beyer B; Larcher A; Michl U; Heinzer H; Huland H; Graefen M; Karakiewicz PI
    Eur J Surg Oncol; 2015 Nov; 41(11):1547-53. PubMed ID: 26117216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection.
    Briganti A; Karakiewicz PI; Chun FK; Gallina A; Salonia A; Zanni G; Valiquette L; Graefen M; Huland H; Rigatti P; Montorsi F
    Eur Urol; 2007 Jun; 51(6):1573-81. PubMed ID: 17293026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy.
    Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Shakir A; Amigoni N; Rizzetto R; Brunelli M; Migliorini F; Siracusano S; Artibani W
    Int Urol Nephrol; 2019 Dec; 51(12):2169-2180. PubMed ID: 31444696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
    Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
    Preisser F; Bandini M; Marchioni M; Nazzani S; Tian Z; Pompe RS; Fossati N; Briganti A; Saad F; Shariat SF; Heinzer H; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Prostate; 2018 May; 78(6):469-475. PubMed ID: 29460290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
    Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
    Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.
    Yaxley JW; Dagher J; Delahunt B; Egevad L; Srigley J; Samaratunga H
    World J Urol; 2018 Jan; 36(1):15-20. PubMed ID: 29116393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.
    Briganti A; Capitanio U; Chun FK; Gallina A; Suardi N; Salonia A; Da Pozzo LF; Colombo R; Di Girolamo V; Bertini R; Guazzoni G; Karakiewicz PI; Montorsi F; Rigatti P
    Eur Urol; 2008 Oct; 54(4):794-802. PubMed ID: 18514383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool.
    Briganti A; Capitanio U; Abdollah F; Gallina A; Suardi N; Bianchi M; Tutolo M; Salonia A; Freschi M; Rigatti P; Montorsi F
    Prostate; 2012 Apr; 72(5):499-506. PubMed ID: 22468270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.
    Briganti A; Abdollah F; Nini A; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Passoni NM; Salonia A; Colombo R; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Jun; 61(6):1132-8. PubMed ID: 22099610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.